Details for Patent: 11,992,514
Which drugs does patent 11,992,514 protect, and when does it expire?
Patent 11,992,514 protects ANGIOMAX RTU and is included in one NDA.
Summary for Patent: 11,992,514
| Title: | Ready-to-use bivalirudin compositions |
| Abstract: | Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin. |
| Inventor(s): | Srikanth Sundaram |
| Assignee: | Maia Pharmaceuticals Inc |
| Application Number: | US16/417,362 |
|
Patent Claim Types: see list of patent claims | Composition; |
Drugs Protected by US Patent 11,992,514
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maia Pharms Inc | ANGIOMAX RTU | bivalirudin | SOLUTION;INTRAVENOUS | 211215-001 | Jul 25, 2019 | RX | Yes | Yes | 11,992,514 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
